Jasper Therapeutics, Inc.
JSPRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Biren Amin | $2.00(+124%) | $0.89 | StreetInsider |
| May 15, 2026 | RBC Capital | $3.00(+257%) | $0.84 | TheFly | |
| Jan 9, 2025 | RBC Capital | Gregory Renza | $48.00(+171%) | $17.71 | TheFly |
| Dec 5, 2024 | BMO Capital | Etzer Darout | $63.00(+193%) | $21.53 | StreetInsider |
| May 6, 2024 | H.C. Wainwright | Emily Bodnar | $65.00(+165%) | $24.52 | StreetInsider |
| Apr 3, 2024 | Evercore ISI | Gavin Clark-Gartner | $65.00(+148%) | $26.20 | StreetInsider |
| Feb 7, 2023 | Cantor Fitzgerald | $6.00(+213%) | $1.92 | Benzinga | |
| Jan 11, 2023 | Credit Suisse | $3.00(+82%) | $1.65 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| TD Cowen | downgrade | Buy →Hold | May 15, 2026 |
| RBC Capital | maintain | Sector Perform | May 15, 2026 |
| Evercore ISI Group | maintain | Outperform | Apr 1, 2026 |
| RBC Capital | maintain | Sector Perform | Nov 11, 2025 |
| Evercore ISI Group | maintain | Outperform | Sep 22, 2025 |
| BTIG | maintain | Buy | Sep 22, 2025 |
| JMP Securities | maintain | Market Outperform | Sep 22, 2025 |
| UBS | maintain | Buy | Aug 15, 2025 |
| BMO Capital | downgrade | Outperform →Market Perform | Jul 8, 2025 |
| Evercore ISI Group | maintain | Outperform | Jul 8, 2025 |
| JMP Securities | maintain | Market Outperform | Jul 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jul 7, 2025 |
| BTIG | maintain | Buy | Jul 7, 2025 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | Jul 7, 2025 |
| William Blair | downgrade | Outperform →Market Perform | Jul 7, 2025 |
| Oppenheimer | maintain | Outperform | May 15, 2025 |
| UBS | maintain | Buy | May 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 10, 2025 |
| JMP Securities | maintain | Market Outperform | Jan 10, 2025 |
| RBC Capital | maintain | Outperform | Jan 9, 2025 |
| JMP Securities | maintain | Market Outperform | Jan 6, 2025 |
| RBC Capital | maintain | Outperform | Dec 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| JMP Securities | maintain | Market Outperform | Oct 15, 2024 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-0.30| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-3.00 | $-0.37 | — | — |
| May 15, 2026 | $-0.04 | $-13.80 | — | — |
| Mar 30, 2026 | $-0.32 | $-23.70 | — | — |
| Nov 11, 2025 | $-1.13 | $-30.30 | — | — |
| Aug 13, 2025 | $-52.20 | $-36.00 | — | — |
| May 12, 2025 | $-1.41 | $-35.10 | — | — |
| Mar 3, 2025 | $-1.62 | $-36.00 | — | — |
| Nov 7, 2024 | $-1.24 | $-32.10 | — | — |
News
REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced a 1-for-30 reverse stock split (“Reverse Split”) of the Company's common stock (“Common Stock”) that will become effective at 12:01 a.m.
Initial Stage 1 data evaluating ven s obafusp alfa in IgAN expected by year-end 2026 Announces e xpansion cohort in patients with FSGS , with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has complet…
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten…
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C.
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders